MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.70
+1.23
+3.20%
After Hours: 39.70 0 0.00% 16:42 05/11 EDT
OPEN
38.27
PREV CLOSE
38.47
HIGH
40.08
LOW
38.06
VOLUME
70.04K
TURNOVER
--
52 WEEK HIGH
56.16
52 WEEK LOW
36.48
MARKET CAP
520.82M
P/E (TTM)
44.73
1D
5D
1M
3M
1Y
5Y
Eagle Pharmaceuticals To Present At The 2021 RBC Capital Markets Global Healthcare Conference
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the
Benzinga · 8h ago
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief...
BusinessWire - BZX · 8h ago
--RBC Trims Price Target on Eagle Pharmaceuticals to $50 From $52, Maintains Outperform Rating
MT Newswires · 19h ago
8-K: EAGLE PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- 0000827871 false 0000827871 2021-05-10 2021-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
10-Q: EAGLE PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
DJ Eagle Pharmaceuticals, Inc.'s CEO Scott Tarriff on Q1 2021 Results -- Earnings Call Transcript >EGRX
Dow Jones · 1d ago
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Miss Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Eagle Pharmaceuticals Reports First Quarter 2021 Results
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced financial results for the three months ended March 31, 2021.
Business Wire · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EGRX. Analyze the recent business situations of Eagle Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EGRX stock price target is 47.33 with a high estimate of 50.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 256
Institutional Holdings: 15.70M
% Owned: 119.67%
Shares Outstanding: 13.12M
TypeInstitutionsShares
Increased
48
753.04K
New
19
98.91K
Decreased
70
982.89K
Sold Out
22
341.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Michael Graves
President/Chief Operating Officer
David Pernock
Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer/Chief Accounting Officer
Brian Cahill
Director
Luciana Borio
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
No Data
About EGRX
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.